Protective Efficacy of the OprF/OprI/PcrV Recombinant Chimeric Protein Against Pseudomonas aeruginosa in the Burned BALB/c Mouse Model

References

• Moradali MF, Ghods S, Rehm BH. Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence. Front Cell Infect Microbiol. 2017;7:39. doi:10.3389/fcimb.2017.0003928261568
   PubMed Web of Science ®Google Scholar
• Nathwani D, Raman G, Sulham K, et al. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2014;3(1):32. doi:10.1186/2047-2994-3-3225371812
   PubMed Web of Science ®Google Scholar
• Yang F, Gu J, Yang L, et al. Protective efficacy of the trivalent Pseudomonas aeruginosa vaccine candidate PcrV-OprI-Hcp1 in murine pneumonia and burn models. Sci Rep. 2017;7:3957. doi:10.1038/s41598-017-04029-528638106
   PubMed Web of Science ®Google Scholar
• Ding C, Yang Z, Wang J, et al. Prevalence of Pseudomonas aeruginosa and antimicrobial-resistant Pseudomonas aeruginosa in patients with pneumonia in mainland China: a systematic review and meta-analysis. Int J Infect Dis. 2016;49:119–128. doi:10.1016/j.ijid.2016.06.01427329135
   PubMed Web of Science ®Google Scholar
• Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents. 2015;45:568–585. doi:10.1016/j.ijantimicag.2015.03.00125857949
   PubMed Web of Science ®Google Scholar
• Mikucionyte G, Zamorano L, Vitkauskiene A, et al. Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania. Eur J Clin Microbiol Infect Dis. 2016;35:195–200. doi:10.1007/s10096-015-2529-026638216
   PubMed Web of Science ®Google Scholar
• Leylabadlo HE, Asgharzadeh M, Aghazadeh M. Dissemination of carbapenemases producing gram negative bacteria in the Middle East. Iran J Microbiol. 2015;7:226.26719779
   PubMedGoogle Scholar
• Döring G, Meisner C, Stern M, et al. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci. 2007;104:11020–11025. doi:10.1073/pnas.070240310417585011
   PubMed Web of Science ®Google Scholar
• Westritschnig K, Hochreiter R, Wallner G, et al. A randomized, placebo-controlled Phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers. Hum Vaccines Immunother. 2014;10:170–183. doi:10.4161/hv.26565
   PubMed Web of Science ®Google Scholar
• François B, Luyt C-E, Dugard A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 2012;40:2320–2326. doi:10.1097/CCM.0b013e31825334f622622405
   PubMed Web of Science ®Google Scholar
• Lu Q, Rouby -J-J, Laterre P-F, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother. 2011;66:1110–1116. doi:10.1093/jac/dkr04621398296
   PubMed Web of Science ®Google Scholar
• Vincent J-L. Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update. Future Microbiol. 2014;9:457–463. doi:10.2217/fmb.14.1024810345
   PubMed Web of Science ®Google Scholar
• Gellatly SL, Hancock RE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis. 2013;67:159–173. doi:10.1111/2049-632X.1203323620179
   PubMed Web of Science ®Google Scholar
• Milla CE, Chmiel JF, Accurso FJ, et al. Anti‐PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol. 2014;49:650–658. doi:10.1002/ppul.2289024019259
   PubMed Web of Science ®Google Scholar
• Tseng T-S, Wang S-H, Chang T-W, et al. Sarkosyl-induced helical structure of an antimicrobial peptide gw-q6 plays an essential role in the binding of surface receptor OprI in Pseudomonas aeruginosa. PLoS One. 2016;11:e0164597. doi:10.1371/journal.pone.016459727727309
   PubMed Web of Science ®Google Scholar
• Chang T-W, Wang C-F, Huang H-J, et al. Key residues of outer membrane protein OprI involved in hexamer formation and bacterial susceptibility to cationic antimicrobial peptides. Antimicrob. Agents Chemother. 2015;59:6210–6222. doi:10.1128/AAC.01406-1526248382
   PubMed Web of Science ®Google Scholar
• Gartner T, Baeten M, Otieno S, et al. Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A. Immunol Lett. 2007;111:26–35. doi:10.1016/j.imlet.2007.04.01017570535
   PubMed Web of Science ®Google Scholar
• Rau H, Revets H, Cornelis P, et al. Efficacy and functionality of lipoprotein OprI from Pseudomonas aeruginosa as adjuvant for a subunit vaccine against classical swine fever. Vaccine. 2006;24(22):4757–4768. doi:10.1016/j.vaccine.2006.03.02816678311
   PubMed Web of Science ®Google Scholar
• Revets H, Pynaert G, Grooten J, et al. Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J. Immunol. 2005;174:1097–1103. doi:10.4049/jimmunol.174.2.109715634935
   PubMed Web of Science ®Google Scholar
• Behrouz B, Mahdavi M, Amirmozafari N, et al. Immunogenicity of Pseudomonas aeruginosa recombinant b-type fagellin as a vaccine candidate: protective efficacy in a murine burn wound sepsis model. Burns. 2016. doi:10.1016/j.burns.2016.03.015
   PubMedGoogle Scholar
• Zhang X, Yang F, Zou J, et al. Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice. Vaccine. 2018;36(8):1047–1054. doi:10.1016/j.vaccine.2018.01.03429406241
   PubMed Web of Science ®Google Scholar
• CLSI C. Performance Standards for Antimicrobial Susceptibility Testing. Clinical Lab Standards Institute; 2016.
   Google Scholar
• Aguilera-Herce J, García-Quintanilla M, Romero-Flores R, et al. A live salmonella vaccine delivering PcrV through the type III secretion system protects against Pseudomonas aeruginosa. mSphere. 2019;4(2):e00116–e00119. doi:10.1128/mSphere.00116-1930996108
   PubMed Web of Science ®Google Scholar
• Hoggarth A, Weaver A, Pu Q, et al. Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa. Drug Des Dev Ther. 2019;13:909. doi:10.2147/DDDT.S189847
   PubMed Web of Science ®Google Scholar
• Nilsson E, Larsson A, Olesen HV, et al. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol. 2008;43:892–899. doi:10.1002/ppul.2087518680179
   PubMed Web of Science ®Google Scholar
• Sato H, Frank D. Multi-functional characteristics of the Pseudomonas aeruginosa type III needle-tip protein, PcrV; comparison to orthologs in other gram-negative bacteria. Front Microbiol. 2011;2:142. doi:10.3389/fmicb.2011.0014221772833
   PubMed Web of Science ®Google Scholar
• Warrener P, Varkey R, Bonnell JC, et al. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. Antimicrob Agents Chemother. 2014;58:4384–4391. doi:10.1128/AAC.02643-1424841258
   PubMed Web of Science ®Google Scholar
• Wang Q, Li H, Zhou J, et al. PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury. Respir Physiol Neurobiol. 2014;193:21–28. doi:10.1016/j.resp.2014.01.00124418353
   PubMed Web of Science ®Google Scholar
• Song Y, Baer M, Srinivasan R, et al. PcrV antibody–antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Eur J Clin Microbiol Infect Dis. 2012;31:1837–1845. doi:10.1007/s10096-011-1509-222187351
   PubMed Web of Science ®Google Scholar
• Weimer ET, Lu H, Kock ND, et al. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. Infect Immun. 2009;77:2356–2366. doi:10.1128/IAI.00054-0919349426
   PubMed Web of Science ®Google Scholar
• Haberstroh J, Gilleland H Jr, von Specht B-U. Effect of anti-OprF-Opri immunoglobulin on APACHE II score in a porcine two-hit model of hemorrhagic shock/resuscitation and pseudomonas aeruginosa sepsis.Eur Surg Res. 2005;37(5):265–273. doi:10.1159/00008923216374008
   PubMed Web of Science ®Google Scholar
• Baumann U, Mansouri E, Von Specht B-U. Recombinant OprF–OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine. 2004;22:840–847. doi:10.1016/j.vaccine.2003.11.02915040936
   PubMed Web of Science ®Google Scholar
• Tylewska S, Hjertén S, Wadström T. Effect of subinhibitory concentrations of antibiotics on the adhesion of Streptococcus pyogenes to pharyngeal epithelial cells. Antimicrob Agents Chemother. 1981;20:563–566. doi:10.1128/AAC.20.5.5637034640
   PubMed Web of Science ®Google Scholar
• Stendahl O, Tagesson C, Magnusson K, et al. Physiochemical consequences of opsonization of Salmonella typhimurium with hyperimmune IgG and complement. Immunology. 1977;32:11.321337
   PubMed Web of Science ®Google Scholar
• Calvinho L, Almeida R, Oliver S. Influence of Streptococcus dysgalactiae surface hydrophobicity on adherence to mammary epithelial cells and phagocytosis by mammary macrophages. J Vet Med Ser B. 1996;43:257–266. doi:10.1111/j.1439-0450.1996.tb00313.x
   Google Scholar
• Pruul H, Lewis G, McDonald PJ. Enhanced susceptibility of gram-negative bacteria to phagocytic killing by human polymorphonuclear leucocytes after brief exposure to aztreonam. J Antimicrob Chemother. 1988;22:675–686. doi:10.1093/jac/22.5.6753209526
   PubMed Web of Science ®Google Scholar
• Kerosuo E, Haapasalo M, Alli K, et al. Ingestion of Bacteroides buccae, Bacteroides oris, Porphyromonas gingivalis, and Fusobacterium nucleatum by human polymorphonuclear leukocytes in vitro. Oral Microbiol Immunol. 1990;5:202–207. doi:10.1111/j.1399-302X.1990.tb00646.x2082243
   PubMedGoogle Scholar
• Maródi L, BURJÁN P, Rozgonyi F. Opsonic requirements and surface hydrophobicity of novobiocin-resistant, coagulase-negative staphylococci. J Med Microbiol. 1990;32:19–24. doi:10.1099/00222615-32-1-192342083
   PubMed Web of Science ®Google Scholar
• Dacheux D, Goure J, Chabert J, et al. Pore‐forming activity of type III system‐secreted proteins leads to oncosis of Pseudomonas aeruginosa‐infected macrophages. Mol Microbiol. 2001;40:76–85. doi:10.1046/j.1365-2958.2001.02368.x11298277
   PubMed Web of Science ®Google Scholar
• Weimer ET, Ervin SE, Wozniak DJ, et al. Immunization of young African green monkeys with OprF epitope 8–OprI–type A-and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine. 2009;27:6762–6769. doi:10.1016/j.vaccine.2009.08.08019744586
   PubMed Web of Science ®Google Scholar
• Gong Q, Ruan M, Niu M, et al. Immune efficacy of DNA vaccines based on oprL and oprF genes of Pseudomonas aeruginosa in chickens. Poult Sci. 2018;97:4219–4227. doi:10.3382/ps/pey30730053150
   PubMed Web of Science ®Google Scholar
• Chuang Wan JZ, Zhao L, Cheng X, et al. Rational design of a chimeric derivative of PcrV as a subunit vaccine against Pseudomonas aeruginosa. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.00781
   Web of Science ®Google Scholar
• Baker SM, Pociask D, Clements JD, et al. Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia. Vaccine. 2019;37:808–816. doi:10.1016/j.vaccine.2018.12.05330638799
   PubMed Web of Science ®Google Scholar
• Hassan R, El-Naggar W, El-Aziz AMA, et al. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa. J Microbiol Immunol Infect. 2018;51:312–320. doi:10.1016/j.jmii.2016.08.01428291719
   PubMedGoogle Scholar